- Home
- GPRO vs ENLV Comparison
GPRO vs ENLV Comparison
Compare GPRO & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPRO | ENLV |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.0M | 149.0M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GPRO | ENLV |
|---|---|---|
| Price | $0.67 | $4.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 5.4M | 280.7K |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $651,542,000.00 | N/A |
| Revenue This Year | $23.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.43 |
| 52 Week High | $3.05 | $7.64 |
Technical Indicators
Market Signals| Indicator | GPRO | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 57.84 |
| Support Level | $0.59 | $0.79 |
| Resistance Level | $0.83 | $7.64 |
| Average True Range (ATR) | 0.05 | 0.59 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 7.75 | 50.64 |
Price Performance
Historical ComparisonAbout GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.